The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Former President Joe Biden was diagnosed with an "aggressive form" of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president's prostate cancer is characterized ...